Abstract: The present disclosure provides a pharmaceutical composition that inhibits the proliferation of a cancer cell, comprising a first compound selected from indole-3-carbinol (I3C), 1-benzyl I3C, or a pharmaceutically acceptable salt or ester thereof, and a second compound that binds to and inhibits: i) an oncogenic RAF polypeptide at a site that is distinct from the site at which the first compound binds; ii) a polypeptide of the RAF signaling pathway; iii) a polypeptide of the Wnt-?-catenin signaling pathway; iv) or a polypeptide of the PI3K/AKT/mTOR signaling pathway. The present disclosure also provides a method of treating cancer in a subject.

Abstract: The invention provides methods and compositions relating to activated Sgk and the association of activated Sgk activity with proliferating cells, including methods for inhibiting the growth of an undesirably proliferating cell by contacting the cell with a specific inhibitor of activated Sgk whereby the amount of activated Sgk activity in the cell is reduced. Specific inhibitors are disclosed, including dominant negative mutants of activated Sgk, an Sgk mutant or fragment thereof comprising an unphosphorylatable residue corresponding to Thr256 of native Sgk, and an active Sgk-specific antibody or antibody fragment, especially intrabody, etc. A wide variety of methods may be used to contact the target cell with the inhibitor, especially introducing into the cell a polynucleotide encoding the inhibitor under conditions whereby the inhibitor is expressed in the cell.

Abstract: The invention provides methods and compositions relating to novel bioactive derivatives of indole-3-carbinol (I3C), including pharmaceuticals comprising a pharmaceutically acceptable excipient and a compound of the general formula: which inhibits tumor cell growth. Methods of inhibiting targeted cell growth include contacting a target cell with a disclosed compound under conditions whereby the growth the target cell is inhibited, and methods for evaluating the growth inhibitory activity of the compounds include contacting a cell with an effective amount of the compound and measuring the CDK6 expression in the cell, wherein a reduction in CDK6 expression correlates with the growth inhibitory activity of the compound.

Abstract: The invention provides methods and compositions relating to activated Sgk and the association of activated Sgk activity with proliferating cells, including methods for inhibiting the growth of an undesirably proliferating cell by contacting the cell with a specific inhibitor of activated Sgk whereby the amount of activated Sgk activity in the cell is reduced. Specific inhibitors are disclosed, including dominant negative mutants of activated Sgk, an Sgk mutant or fragment thereof comprising an unphosphorylatable residue corresponding to Thr256 of native Sgk, and an active Sgk-specific antibody or antibody fragment, especially intrabody, etc. A wide variety of methods may be used to contact the target cell with the inhibitor, especially introducing into the cell a polynucleotide encoding the inhibitor under conditions whereby the inhibitor is expressed in the cell.

Abstract: The invention provides methods and compositions relating to novel bioactive derivatives of indole-3-carbinol (I3C), including pharmaceuticals comprising a pharmaceutically acceptable excipient and a compound of the general formula: 1

Abstract: The invention provides methods and compositions relating to activated Sgk and the association of activated Sgk activity with proliferating cells, including methods for inhibiting the growth of an undesirably proliferating cell by contacting the cell with a specific inhibitor of activated Sgk whereby the amount of activated Sgk activity in the cell is reduced. Specific inhibitors are disclosed, including dominant negative mutants of activated Sgk, an Sgk mutant or fragment thereof comprising an unphosphorylatable residue corresponding to Thr 256 of native Sgk, and an active Sgk-specific antibody or antibody fragment, especially intrabody, etc. A wide variety of methods may be used to contact the target cell with the inhibitor, especially introducing into the cell a polynucleotide encoding the inhibitor under conditions whereby the inhibitor is expressed in the cell.

Abstract: The invention provides methods and compositions relating to novel bioactive derivatives of indole-3-carbinol (I3C), including pharmaceuticals comprising a pharmaceutically acceptable excipient and a compound of the general formula: which inhibits tumor cell growth. Methods of inhibiting targeted cell growth include contacting a target cell with a disclosed compound under conditions whereby the growth the target cell is inhibited, and methods for evaluating the growth inhibitory activity of the compounds include contacting a cell with an effective amount of the compound and measuring the CDK6 expression in the cell, wherein a reduction in CDK6 expression correlates with the growth inhibitory activity of the compound.

Abstract: The invention provides methods and compositions relating to novel bioactive derivatives of indole-3-carbinol (I3C), including pharmaceuticals comprising a pharmaceutically acceptable excipient and a compound of the general formula: ##STR1## which inhibits tumor cell growth. Methods of inhibiting targeted cell growth include contacting a target cell with a disclosed compound under conditions whereby the growth the target cell is inhibited, and methods for evaluating the growth inhibitory activity of the compounds include contacting a cell with an effective amount of the compound and measuring the CDK6 expression in the cell, wherein a reduction in CDK6 expression correlates with the growth inhibitory activity of the compound.

Abstract: The invention provides methods and compositions relating to novel bioactive derivatives of indole-3-carbinol (I3C), including pharmaceuticals comprising a pharmaceutically acceptable excipient and a compound of the general formula: ##STR1## which inhibits tumor cell growth. Methods of inhibiting targeted cell growth include contacting a target cell with a disclosed compound under conditions whereby the growth the target cell is inhibited, and methods for evaluating the growth inhibitory activity of the compounds include contacting a cell with an effective amount of the compound and measuring the CDK6 expression in the cell, wherein a reduction in CDK6 expression correlates with the growth inhibitory activity of the compound.